JP Morgan Chase’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-25,000
Closed -$3.42M – 7456
2024
Q2
$3.42M Buy
+25,000
New +$3.42M ﹤0.01% 3337
2020
Q2
– Sell
-129,600
Closed -$10.4M – 5430
2020
Q1
$10.4M Buy
+129,600
New +$13.4M ﹤0.01% 1708
2019
Q2
– Sell
-100,800
Closed -$9.06M – 5799
2019
Q1
$9.06M Buy
+100,800
New +$8.73M ﹤0.01% 2134
2016
Q1
– Sell
-1,100
Closed -$78K – 4712
2015
Q4
$78K Buy
+1,100
New +$74K ﹤0.01% 3827

Other funds holding DGX

JP Morgan Chase's DGX Position: Q2 2026 in Review

JP Morgan Chase reduced its Quest Diagnostics (DGX) stake by 8.5% in Q2 2026, selling an estimated $64M and leaving 3,520,438 shares worth $749M. The position accounts for 0.04% of the portfolio, ranked #346.

JP Morgan Chase first reported a position in DGX in Q2 2013 and has held it in 53 quarters since. The position peaked at $823M in Q3 2025. 1,111 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • JP Morgan Chase held 3,520,438 shares of Quest Diagnostics worth $749M as of Q2 2026.
  • JP Morgan Chase sold 326,018 Quest Diagnostics shares in Q2 2026, an estimated $64M.
  • Quest Diagnostics made up 0.04% of JP Morgan Chase's portfolio in Q2 2026, its #346 holding.
  • JP Morgan Chase first reported a position in Quest Diagnostics in Q2 2013 and has held it in 53 quarters since.
  • JP Morgan Chase's Quest Diagnostics position peaked at $823M in Q3 2025.
  • 1,111 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.